US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom

US-based Axiom Biosciences is considering an initial public offering in Hong Kong to utilize China’s expanding clinical development capabilities, marking a rare move for an American biotechnology firm. Simultaneously, sources report that China's Zhongji Innolight is planning its own initial public offering in Hong Kong, with an estimated value of $8 billion. Both companies are targeting the Hong Kong market to facilitate their growth and tap into the region's significant biotech and financial opportunities.